Provided By GlobeNewswire
Last update: Mar 20, 2025
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.
Read more at globenewswire.comNYSEARCA:NRXS (11/10/2025, 10:17:12 AM)
2.55
+0.01 (+0.39%)
Find more stocks in the Stock Screener


